EUVIMEDEUVIMED entdecken
Crossref

Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment

Bao Loc Nguyen, Cao Dai Phung, Duc-Vinh Pham, Ngoc Duy Le, Jee-Heon Jeong, Jeonghwan Kim, Ju-Hyun Kim, Jae-Hoon Chang, Sung Giu Jin, Han-Gon Choi, Sae Kwang Ku, Jong Oh Kim

Journal of Controlled Release · 2023

DOI: 10.1016/j.jconrel.2023.08.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Bao Loc Nguyen und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea. Hauptthemen laut MEDLINE: Toll-Like Receptor 3, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: NRF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is highly aggressive and has no standard treatment. Although being considered as an alternative to conventional treatments for TNBC, immunotherapy has to deal with many challenges that hinder its efficacy, particularly the poor immunogenic condition of the tumor microenvironment (TME). Herein, we designed a liposomal nanoparticle (LN) platform that delivers simultaneously toll-like receptor 7 (imiquimod, IQ) and toll-like receptor 3 (poly(I:C), IC) agonists to take advantage of the different toll-like receptor (TLR) signaling pathways, which enhances the condition of TME from a "cold" to a "hot" immunogenic state. The optimized IQ/IC-loaded LN (IQ/IC-LN) was effectively internalized by cancer cells, macrophages, and dendritic cells, followed by the release of the delivered drugs and subsequent stimulation of the TLR3 and TLR7 signaling pathways. This stimulation encouraged the secretion of type I interferon (IFN-α, IFN-β) and CXCLl0, a T-cell and antigen-presenting cells (APCs) recruitment chemokine, from both cancer cells and macrophages and polarized macrophages to the M1 subtype in in vitro studies. Notably, systemic administration of IQ/IC-LN allowed for the high accumulation of drug content in the tumor, followed by the effective uptake by immune cells in the TME. IQ/IC-LN treatment comprehensively enhanced the immunogenic condition in the TME, which robustly inhibited tumor growth in tumor-bearing mice. Furthermore, synergistic antitumor efficacy was obtained when the IQ/IC-LN-induced immunogenic state in TME was combined with anti-PD1 antibody therapy. Thus, our results suggest the potential of combining 2 TLR agonists to reform the TME from a "cold" to a "hot" state, supporting the therapeutic efficacy of immune checkpoint inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 3Triple Negative Breast NeoplasmsHumansAnimalsMiceAdjuvants, ImmunologicLiposomesPoly I-CImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

Immune checkpoint inhibitorsImmunotherapyLiposomal formulationToll-like receptor agonistTriple-negative breast cancer

Substanzen

Toll-Like Receptor 3Adjuvants, ImmunologicLiposomesPoly I-C

Autor:innen und Institutionen

  • College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
  • Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon 16419, Republic of Korea.
  • Department of Pharmaceutical Engineering, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Republic of Korea.
  • College of Pharmacy & Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan 15588, Republic of Korea.
  • College of Korean Medicine, Daegu Haany University, Gyeongsan 38610, Republic of Korea.
  • College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea. Electronic address: jongohkim@yu.ac.kr.

Förderung

  • NRF

Zitieren

APA

Nguyen, B. L., Phung, C. D., Pham, D. V., Le, N. D., Jeong, J. H., Kim, J., Kim, J. H., Chang, J. H., Jin, S. G., Choi, H. G., Ku, S. K., & Kim, J. O. (2023). Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.08.006

Vancouver

Nguyen BL, Phung CD, Pham DV, Le ND, Jeong JH, Kim J, et al. Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.08.006

BibTeX
@article{Nguyen2023,
  author = {Nguyen, Bao Loc and Phung, Cao Dai and Pham, Duc-Vinh and Le, Ngoc Duy and Jeong, Jee-Heon and Kim, Jeonghwan and Kim, Ju-Hyun and Chang, Jae-Hoon and Jin, Sung Giu and Choi, Han-Gon and Ku, Sae Kwang and Kim, Jong Oh},
  title = {Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment},
  journal = {Journal of Controlled Release},
  year = {2023},
  doi = {10.1016/j.jconrel.2023.08.006}
}
Kostenlos starten →